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The objective of this investigation was to develop a new 
methodology using 19F-magnetic resonance spectroscopy 
(MRS) to measure the in vivo percutaneous absorption of 
flurbiprofen through hairless rat skin. A 2% W /V flurbipro-
fen gel (Klucel HF, hydroxypropyl cellulose 1.5% to 2% 
W IV) containing isopropyl alcohol, water, and propylene 
glycol (55:35: 10 v /v Iv) was prepared. A 2-mg dose (100 mg 
of gel) was applied to the skin of the lower back of an anesthe-
tized hairless rat, contained with a rubber o-rin g , and oc-
cluded with a lexan plastic cover slip. The animal was placed 
On an MR surface coil (3.5-cm diameter tuned to 19F) and 
measurements taken continuously over approximately 3 h in 
10-min intervals with a 2-tesla GE CSI nuclear magnetic 
resonance (NMR) spectrometer. 
M ost existing in vivo percutaneous drug studies re-quire the use of radiolabeled materials or the de-velopment of sensitive drug assays to assess drug absorption. Many investigators use in vivo or in vitro animal models to study drug diffusion prior 
to conducting human studies. Problems often develop going from 
the animal models in vivo or in vitro to obtaining favorable results in 
humans. There is a need for an easy in vivo method of studying drug 
diffusion and absorption that is readily transferable from an in vivo 
animal model to humans. The novel use of fluorine magnetic reso-
nance spectroscopy (MRS) to measure the disappearance of flurbi-
profen in vivo in the hairless rat provides considerable success in 
achieving this goal [1] . 
Flurbiprofen, 2-{2-fluoro-4-biphenyl)propionic acid, is a non-
steroidal anti-inflammatory drug with analgesic and antipyretic ac-
tivities. The effective oral pharmacologic dose has been reported to 
be between 0.04 and 0.47 mg/kg [2]. Flurbiprofen, which is at least 
200 times more potent than acetylsalicylic acid, is used to treat 
various diseases such as gout, osteoarthritis [2], rheumatoid arthritis 
[3], and periodontitis [4]. Plasma concentration of 5 ,ug/ml at 0.5 h 
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Abbreviations: 
HPLC: high-performance liquid chromatography 
MR: magnetic resonance 
MRS: magnetic resonance spectroscopy 
% W IV: percent weight in volume 
ppm: parts per million 
One measures the disappearance ofMR signal intensity per 
interval, which directly relates to the percent of drug disap-
pearance over time, which in turn was converted to a flux 
value. The flux of flurbiprofen in vivo was found to be 95 ± 
22 Jig/ cm2 /h. This is approximately four times greater than 
the flux of flurbiprofen through excised human skin reported 
by Akhter and Barry (22 ± 14 Jig/cm2/h). 
This new in vivo method measures drug disappearance and 
can be readily transferred to man. This method may be 
adapted to study other fluorine compounds or other nuclei 
with magnetic properties. It avoids exposure of a patient or 
animal to the radiation used in x-ray fluorescence methods or 
to 14C_ or 3H-radiolabeled drugs. ] Invest Dermatol 99:431-
434, 1992 
to 14 ,ug/ml at 3 h have been reported following topical application 
of the same gel formulation to the hairless rat. * Serial blood samples 
were collected in the study and analyzed for flurbiprofen by HPLC. 
Flurbiprofen acts as a potent prostaglandin synthesis inhibitor and 
prevents the migration ofleukocytes into inflamed areas [5]. How-
ever, there are unwanted systemic side effects such as lightheaded-
ness, headache, and tiredness with flurbiprofen. These side effects 
are similar to those of other non-steroidal anti-inflammatory agents. 
Gastrointestinal side effects have also been reported to include con-
stipation, abdominal discomfort, dyspepsia, and other complaints 
[6]. To avoid or decrease the possibility of these systemic side effects, 
the anti-inflammatory and the other favorable pharmacologic ef-
fects of flurbiprofen have been studied following topical administra-
tion [17] . Black et al [7] reported reduced or complete suppression of 
erythema with topical flurbiprofen but could not show that the 
anti-inflammatory effect was correlated to a reduction in prostaglan-
dins. 
The objective of this study was to explore and develop a new 
methodology incorporating 19F-MRS to determine the in vivo per-
cutaneous absorption of flurbiprofen applied topically. This method 
is non-invasive and animals may be used repeatedly for they do not 
have to be sacrificed upon completion of an experiment. 
MATERIALS AND METHODS 
Animals Female hairless rats, approximately 6 to 8 months old 
and weighing between 250 and 350 g, were purchased from 
Charles River Laboratories, Portage, MI. 
• Nanavaty M: Percutaneous Absorption of Flurbiprofen (thesis). Univer-
sity Microfilms International, catalogue number 9015726, Ann Arbor, MI, 
1989. 
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Chemicals Flurbiprofen was kindly provided by The Upjohn 
Pharmaceutical Company, Kalamazoo, MI (lot 0498F). Because 19F 
is an abundant and naturally occurring isotope of fluorine, no special 
synthesis of flurbiprofen was needed for our studies. Pentobarbital 
(Nembutal) was used as an anesthetic agent to provide chemical 
restraint. 
Experimental Procedure Pentobarbital, 25 to 40 mg/kg (3% 
solution of Nembutal), was given intraperitoneally as an initial anes-
thetic dose. Additional doses, if necessary, were given via an abdomi-
nal catheter. A topical formulation of 2% W /V flurbiprofen gel 
(hydroxypropyl cellulose 1.5% to 2% W IV), containing isopropyl 
alcohol, water, and propylene glycol (55:35:10 v/v/v), was pre-
pared and a 2-mg dose (100 mg of gel) applied to the skin of the 
lower back of an anesthetized hairless rat. 
NMR Spectrometer A 2-tesla GE CSI NMR spectrometer was 
used to measure the disappearance (percutaneous absorption) of 
flurbiprofen from the application site. The fluorine resonance fre-
quency at this field is 81 MHz. All experiments were conducted 
with a 3.5-cm diameter single-turn copper surface coil. 
Control MRS Measurements Flurbiprofen, 2 mg in 100 mg of 
gel, was contained inside a rubber o-ring (2.0 cm in diameter), 
which was placed between two lexan plastic covers lips. The flurbi-
profen gel-Iexan preparation was placed on the MR surface coil and 
measurements taken continuously over 4 h. Typical conditions 
were 25 I1sec pulse, 1000 msec repetition rate, and 10,000 hertz 
(Hz) sweep width. Sodium fluoride from commercial toothpastes 
was used to judge chemical shifts and, where appropriate, one peak 
was chosen as an internal reference at 0 ppm. 
In Vivo MRS Spectroscopy As magnets must have their field 
adjusted or "shimmed" to obtain maximal signal, we used a proce-
dure of preshimrning before application of the drug in order to 
minimize the time between drug application and the collection of 
data. An anesthetized hairless rat was placed on a plexiglass platform 
in a cradle that fits into the magnet. The NMR copper surface coil 
also fits onto the platform and the dosing site of the rat was posi-
tioned over the coil. Although the coil was tuned for fluorine (81 
MHz), the concentration of water in the animal is so high (± 80 M) 
that it can still record some of the signal from the protons in water 
and fat when they are excited by the proton frequency (85 MHz). 
This signal is then used to shim the magnetic field to best uniform-
ity, i.e., the sharpest water signal. Single 100-l1sec pulses, 0.5 sec-
100 50 o 
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Figure 1. Flurbiprofen magnetic resonance spectroscopy signal with back-
ground. Plot of intensity versus ppm. The 19F peak resonates at + 43.0 ppm, 
based on the 81 MHz 19F magnetic resonance signal. A single peak is very 
intense and stays intense throughout the course of the in vitro experiment. 
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Figure 2. Plot of peak intensity versus time for hairless rat 4. Each individ-
ual curve is the average of 512 signals collected over a 10-min period as 
described in Materia ls and Methods. This figure is a representative sample of 
data presented in this manner that was acquired for all five animals. 
onds apart, were used for shimming. After shimming, the rat was 
removed from the NMR bore and prepared for an experimen~. 
We note that the gross proton signal of the preshim, which Yields 
a proton profile of skin, has similar ratios of water-to-fat signals aJ the water to alcohol to - CHz - resonances (from Klucel) in the ge 
preparation. The 19F surface copper coil measures predominately 
the amount of flurbiprofen that remains within one radius of the 
coil. The bulk of the signal will be from flurbiprofen on top of t~e 
skin [8]. Because flurbiprofen in the gel and flurbiprofen in the skin 
(epidermis) should be in a similar water/lipid environment, .we 
make the assumption there will be no large differences in relaxatl?'J 
time between these two environments. Consequently, any partla 
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Figure 3. Plot of percent flurbiprofen versus time. Top curve for hairlesd r:: 
3 (trial 1) and bottom curve for hairless rat 4. Curves are representatlve of a 
from n = 5 rats. 
VOL. 99, NO.4 OCTOBER 1992 
~ ,oa N 
E 
u 110 
"-
'" 2- '40 
C 
w 120 
ID 
0:: 
0 '00 
~ 10 
~ 10 
0 
0:: 
n. 
40 
iii 10 0:: 
::> 
• ~ 0 
0.000 CI.SOO '.000 UOO 2.000 uoo 
TIME (HOURS) 
N' 240 
E 220 u 
"- 200 .,. 
2- 110 
0 
W 110 
ID 
It: 
0 
140 
Vl 110 m 
..: 100 
Z 0 ~ 10 0 0 10 0 It: 0 
n. 40 iii 
0 0 It: 20 0 ::> 
~ 0 
0.000 O,SOO '.000 ,.>00 2-000 UOO 3.000 3'soo 
TIME (HOURS) 
Figure 4. Flux curves of flurbiprofen absorption. Plot of amount absorbed 
(ug) per cm2 versus time (h). Top curve for hairless rat 3 (trial 1). Bottom CIIrve 
for hairless rat 4. Data from corresponding curves in Fig 3 (rats 3 [trial 1] and 
4) were used to construct these absorption curves so that in vivo flux could be 
determined from the linear portion of the slope (solid circles) . The regression 
curves include the last zero value prior to obtaining absorption values. 
saturation factors should be small and of the same order of magni-
tude. 
The lower back of the hairless rat was washed with distilled water 
and a gauze sponge. The flurbiprofen gel was applied to the skin 
Within the rubber o-ring, covered with a lexan plastic cover, and 
taped to the skin. The rat was placed on the platform in the cradle 
over the surface coil and the cradle was placed in the magnet bore. 
After replacing the cradle, another quick shim was performed and 
the resonance frequency changed to that of19F. Measurements were 
taken continuously for 3 to 4 h in 10-min intervals or until the 
animal moved. Spectra from 512 scans accumulated over 10 min 
Were averaged and then processed by Fourier transformation. Typi-
cal conditions were the same as previously mentioned except that 
the sweep width was decreased to 5000 Hz. 
RESULTS 
In Vitro MRS A sharp peak for flurbiprofen was detected at 
+ 43.0 ppm relative to sodium fluoride after 50 to 100 accumula-
tions (Fig 1). The peak intensity (peak height and area under the 
curve) remained constant over the measurement period. Presented 
. in Fig 1 is a typical flurbiprofen signal to background noise that the 
spectrometer measures for the fluorine drug molecules. 
In Vivo MRS Following application of the flurbiprofen gel to 
the rat, 19F-flurbiprofen peaks were accumulated in lO-min inter-
vals and the collected signals processed by Fourier transformation. 
'fhe area under the averaged flurbiprofen peak was integrated using 
the program software. The computer-generated averaged peaks 
Were plotted consecutively to show the loss or disappearance of 
flurbiprofen over time. The decrease in peak height and in area 
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Table I. In Vivo Flux and Lag Time of Flurbiprofen Through 
Hairless Rat Skin 
Animal Number Flux (ug/cm2/ h)' Lag Time (h) 
Rat 1 68 
Rat 2 
Trial l ' 99 0.17 
Trial 2 98 2.59 
Rat 3 
Trial l ' 85 1.25 
Trial 2 105 1.31 
Rat 4 85 1.23 
Rat 5 127 1.56 
Mean ± SDd 95 ±22 1.36 ± 0.15 
• Flux was determined (as described in Materials a"d Methods) from the slope of the 
steady-state portion of the linear-regression curve from a plot of the amount absorbed 
per cm' versus time curve (Fig 4). 
, Lag time for rat 1 was a negative value and not included in calculation of mean. 
, Experiment on rats 2 and 3 were repeated to study reproducibility of results. 
J SO, standard deviation; n = 5 and n = 4 (mean values were obtained from trials 1 
and 2 for rats 2 and 3, then these mean values were used with other values) for flux and 
lag time calculations, respectively. 
under the curve was indicative of absorption through the rat's skin 
(Fig 2). 
The decrease in the intensity of the flurbiprofen signal over time 
was converted to a percent of total amount applied and plotted as the 
percent flurbiprofen present against time (Fig. 3A, rat 3 [triall] and 
B, rat 4). 
Flurbiprofen flux was determined by first converting the percent 
lost to a microgram amount absorbed per unit area and plotting the 
results against time (Fig 4A,B). The flux value was determined from 
the steady-state (linear) portion of a computer-generated linear-
regression curve. The individual flux values are given in Table I. 
The mean flurbiprofen flux in vivo was 95 ± 22 Jlg/cm2/h (n = 5) 
and had a mean lag time of 1.36 ± 0.15 h (n = 4). The in vivo 
flurbiprofen flux was compared to in vitro flux determined with 
excised human skin and both are given in Table II. 
DISCUSSION 
\9F-MRS was found to be a useful non-invasive in vivo method to 
measure the percutaneous flux of flurbiprofen through hairless rat 
skin. The intensity of the fluorine signal measured by the copper 
surface coil was strong and specific. The signal-to-background 
noise, presented in Fig 1, allows for easy detection and quantifica-
tion of the fluorine-drug molecules. 
The flurbiprofen gel appeared to be stabile, for no new fluorine 
peaks were detected. One would expect a new peak if the drug were 
to react with components of the gel, forming a new entity. Because 
the gel contained 55% isopropyl alcohol, there was some concern 
that the alcohol might evaporate (over 4 h, even with occlusion) 
and cause the flurbiprofen to precipitate out of the gel. This might 
lead investigators to assume they were measuring disappearance. 
However, the gel remained clear and did not turn cloudy or dis-
Table II. In Vivo/In Vitro Comparison of Flurbiprofen Flux 
Through Human and Hairless Rat Skin 
Method 
Excised Human Skin (in vitro) 
Hairless Rat (MRS) (in vivo) 
• Akhter, Barry [9) . 
'n = 5. 
Flux (ug/cm2/h) 
22 ± 14' 
95 ± 221 
434 LEE ET AL 
color. The peak height and area under the curve for the controls did 
not change, indicating the drug and gel were stabile during the 
experiment. 
This MRS method measures total fluorine drug over time. The 
data obtained from all hairless rat experiments (n = 5) exhibited a 
decrease in peak intensity (Fig 2). The amount (2 mg) of flurbipro-
fen present at time zero (peak intensity and total area under the 
curves) was set at 100%. It was apparent that the peak height and 
area under the fluorine-flurbiprofen curve decreased over the 3 - 4-
h period. The percent remaining at the application site over time 
(calculated from the dose applied) is presented in Fig 3. 
The amount of drug that disappeared was also converted to a 
microgram amount absorbed and plotted against time to obtain the 
percutaneous drug flux. (This is similar to a plot of drug absorbed 
per unit area against time.) One obtains a relationship where the 
slope of the curve represents the flux. The mean flux value of flurbi-
profen in vivo was found to be 95 ± 22 /lg/cm2/h (n = 5). 
The flux for flurbiprofen in this study was approximately four 
times the in vitro flux through excised human skin (22 ± 14 /lg/ 
cm2/h) reported by Akhter and Barry [9]. Because the hairless 
rat has been suggested as an appropriate model for human skin 
studies [10,11], one might suspect that the flux value would be 
more similar. However, this MRS method utilizes an in vivo system 
with a vascular and well-perfused dermis that presents optimal 
sink conditions compared to saline or buffers used with in vitro 
human skin experiments. Between the differences in techniques and 
the two types of skin studied, a factor of four difference does not 
seem unreasonable. One might speculate that this in vivo MRS 
method in the rat may be more predictive of results in man in 
VIVO . 
There are several advantages ofI9F-MRS: the animals do not have 
to be sacrificed following an experiment or sacrificed merely to 
obtain tissue for an in vitro experiment; animals may be used repeat-
edly to study reproducibility of the results; the methods may be used 
to measure absorption of drug applied topically or to assess/compare 
bioavailability (or flux) of other fluorine-containing compounds; 
and other nuclei with magnetic properties may also be studied (e.g., 
I3C-enriched compounds, 31p, and others). Another important ad-
vantage of this technique is that the method can be readily trans-
ferred to humans using larger or perhaps stronger magnetic reso-
nance imaging machines. 
The methods also appear to be of value in following drug absorp-
tion, distribution, and even metabolism after oral or parenteral ad-
ministration [12,13]. Carrington et al reported the use oPIP-MRS 
to follow the absorption of triphenyl phosphite and tri-o-cresyl 
phosphate after intramuscular injection [12] . We are currently in-
vestigating the use of MRS to assess/compare the bioavailability of 
various proprietary and generic topical steroid formulations. MRS 
might provide a more objective and quantitative method of evaluat-
ing topical steroids than the more subjective test that measures vaso-
constriction in the skin [14]. One problem that may have to be 
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addressed would be the sensitivity of the molecule of interest as 
measured by MRS. 
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